110 related articles for article (PubMed ID: 34278497)
1. EphA8 inhibits cell apoptosis via AKT signaling and is associated with poor prognosis in breast cancer.
Wang GH; Ni K; Gu C; Huang J; Chen J; Wang XD; Ni Q
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34278497
[TBL] [Abstract][Full Text] [Related]
2. EphA8 acts as an oncogene and contributes to poor prognosis in gastric cancer via regulation of ADAM10.
Wang Y; Zhou N; Li P; Wu H; Wang Q; Gao X; Wang X; Huang J
J Cell Physiol; 2019 Nov; 234(11):20408-20419. PubMed ID: 31026069
[TBL] [Abstract][Full Text] [Related]
3. EphA8 is a Prognostic Factor for Oral Tongue Squamous Cell Carcinoma.
Liu L; Wang X; Ge W
Med Sci Monit; 2018 Oct; 24():7213-7222. PubMed ID: 30300334
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation.
Dastmalchi N; Safaralizadeh R; Hosseinpourfeizi MA; Baradaran B; Khojasteh SMB
Mol Biol Rep; 2021 Feb; 48(2):1345-1357. PubMed ID: 33555529
[TBL] [Abstract][Full Text] [Related]
5. TRIM59 overexpression correlates with poor prognosis and contributes to breast cancer progression through AKT signaling pathway.
Liu Y; Dong Y; Zhao L; Su L; Diao K; Mi X
Mol Carcinog; 2018 Dec; 57(12):1792-1802. PubMed ID: 30175868
[TBL] [Abstract][Full Text] [Related]
6. Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
Xu JH; Wang Y; Xu D
Cancer Biomark; 2019; 25(2):193-201. PubMed ID: 31104012
[TBL] [Abstract][Full Text] [Related]
7. Silencing ARHGAP9 correlates with the risk of breast cancer and inhibits the proliferation, migration, and invasion of breast cancer.
Wang T; Ha M
J Cell Biochem; 2018 Sep; 119(9):7747-7756. PubMed ID: 29905031
[TBL] [Abstract][Full Text] [Related]
8. PLCA8 suppresses breast cancer apoptosis by activating the PI3k/AKT/NF-κB pathway.
Mao M; Chen Y; Jia Y; Yang J; Wei Q; Li Z; Chen L; Chen C; Wang L
J Cell Mol Med; 2019 Oct; 23(10):6930-6941. PubMed ID: 31448883
[TBL] [Abstract][Full Text] [Related]
9. EphA8 is a prognostic marker for epithelial ovarian cancer.
Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
[TBL] [Abstract][Full Text] [Related]
10. MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.
Li Z; Li C; Wu Q; Tu Y; Wang C; Yu X; Li B; Wang Z; Sun S; Sun S
Cell Death Dis; 2021 Jan; 12(1):97. PubMed ID: 33462219
[TBL] [Abstract][Full Text] [Related]
11. MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer.
Liu MM; Li Z; Han XD; Shi JH; Tu DY; Song W; Zhang J; Qiu XL; Ren Y; Zhen LL
Sci Rep; 2017 Nov; 7(1):15929. PubMed ID: 29162879
[TBL] [Abstract][Full Text] [Related]
12. The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway.
Yunwen C; Shanshan G; Zhifei B; Saijun C; Hua Y
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33899120
[TBL] [Abstract][Full Text] [Related]
13. Integrating bioinformatics and experimental models to investigate the mechanism of the chelidonine-induced mitotic catastrophe via the AKT/FOXO3/FOXM1 axis in breast cancer cells.
Li H; Tang X; Sun Z; Qu Z; Zou X
Biomol Biomed; 2024 May; 24(3):560-574. PubMed ID: 37976368
[TBL] [Abstract][Full Text] [Related]
14. Livin promotes progression of breast cancer through induction of epithelial-mesenchymal transition and activation of AKT signaling.
Li F; Yin X; Luo X; Li HY; Su X; Wang XY; Chen L; Zheng K; Ren GS
Cell Signal; 2013 Jun; 25(6):1413-22. PubMed ID: 23524337
[TBL] [Abstract][Full Text] [Related]
15. Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing.
Zhu X; Feng J; Fu W; Shu X; Wan X; Liu J
Int J Mol Med; 2020 Jun; 45(6):1838-1850. PubMed ID: 32186756
[TBL] [Abstract][Full Text] [Related]
16. Abnormally elevated ubiquilin‑1 expression in breast cancer regulates metastasis and stemness via AKT signaling.
Feng X; Cao A; Qin T; Zhang Q; Fan S; Wang B; Song B; Yu X; Li L
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34528694
[TBL] [Abstract][Full Text] [Related]
17. RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers.
Pathak GP; Shah R; Kennedy BE; Murphy JP; Clements D; Konda P; Giacomantonio M; Xu Z; Schlaepfer IR; Gujar S
Mol Ther; 2018 Aug; 26(8):2019-2033. PubMed ID: 30078441
[TBL] [Abstract][Full Text] [Related]
18. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
[TBL] [Abstract][Full Text] [Related]
19. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
20. ROR2 knockdown suppresses breast cancer growth through PI3K/ATK signaling.
Guo M; Ma G; Zhang X; Tang W; Shi J; Wang Q; Cheng Y; Zhang B; Xu J
Aging (Albany NY); 2020 Jul; 12(13):13115-13127. PubMed ID: 32614787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
